Navigation Links
SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
Date:9/5/2008

/p>

Sunesis is a clinical-stage biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

Safe Harbor Statement

This press release contains forward-looking statements, including without limitation statements related to the potential payment of future milestones to Sunesis under its license agreement with SARcode. Words such as "will," "potential," "look forward," "ifs" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that SARcode's drug development activities could be halted or delayed significantly for various reasons and the risk that Sunesis may not receive any future payments from SARcode under the license agreement. These and other risk factors are discussed under "Risk Factors," including the risk factors entitled "The commercial success of products resulting from our collaborations, if any, depends in whole or in part on the development and marketing efforts of our collaboration partners, over which we have limited control. If our collaborations are unsuccessful, our potential to generate future revenue from the sale of these products would be significantly reduced" and "If conflicts of interest arise between our collaborati
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
2. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
3. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
8. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
9. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
10. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
11. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb ... in ambulances and other transport vehicles, an advanced and portable UV ... personnel for the first time. In order to ... these deadly pathogens, West Palm Beach Fire ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... revised Concepts in Clinical Pharmacokinetics , a web-based ... Georgia. Developed in cooperation with the American Society of ... Continuing Education and College of Pharmacy, the new Online ... fundamental principles of absorption, distribution, metabolism, and the elimination ...
... preeminent law office of Nurenberg, Paris, Heller & ... Johnson & Johnson,s artificial joint replacement company DePuy ... damages resulting from the company,s now-recalled hip replacement ... District of Ohio, Eastern Division) ...
Cached Medicine Technology:Newly Revised Concepts in Clinical Pharmacokinetics Web-Based Continuing Education Course Offered by the University of Georgia 2Newly Revised Concepts in Clinical Pharmacokinetics Web-Based Continuing Education Course Offered by the University of Georgia 3DePuy Orthopaedics Accused of Deceiving Hip Replacement Patients 2DePuy Orthopaedics Accused of Deceiving Hip Replacement Patients 3
(Date:7/8/2014)... LIVERMORE, Calif. The Department of Defense,s Defense ... National Laboratory (LLNL) up to $2.5 million to ... to record and stimulate neurons within the brain ... week. , The research builds on the understanding ... in certain regions of the brain encode information, ...
(Date:7/8/2014)... times higher when auditors were visible to healthcare workers ... a study in a major Canadian acute care hospital. ... effect in hand hygiene compliance monitoring using an electronic ... in the BMJ Quality & Safety Journal , ... study as part of her Master,s thesis while a ...
(Date:7/8/2014)... have discovered a biomarker that could give expecting mothers ... reliably predict that a pregnant woman may develop preeclampsia, ... pregnancy. , Preeclampsia is a cardiovascular disorder generally occurring ... delivery, creating immediate and potentially lifelong risks to both ... protein in the urine, and is typically diagnosed in ...
(Date:7/8/2014)... Johnson Foundation/Harvard School of Public Health (HSPH) poll released ... lives finds that about half of the public (49%) ... experience in the past year. Nearly half (43%) reported ... More than half of those who experienced a great ... many overall responsibilities and financial problems were contributors (54% ...
(Date:7/8/2014)... Military physicians will soon pick up joysticks instead of textbooks ... serious health threats. , James Gerard, M.D., a professor of ... from the Department of Defense Office of Naval Research ... video game that will train physicians on pediatric emergency room ... one of the most popular tools gaming to ...
Breaking Medicine News(10 mins):Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3Health News:UI researchers find early predictor for preeclampsia 2Health News:UI researchers find early predictor for preeclampsia 3Health News:Poll finds health most common major stressful event in Americans' lives last year 2Health News:Poll finds health most common major stressful event in Americans' lives last year 3Health News:Poll finds health most common major stressful event in Americans' lives last year 4Health News:Save, don't kill: SLU pediatrician to develop educational video game for training military physician 2
... multiple sclerosis (MS), the myelin that surrounds the axons of ... resulting in slowed and disrupted nerve impulses and, ultimately, axon ... major component of the myelin sheath and when used as ... which is used as an animal model of human MS. ...
... of Nepalese doctors has developed a drug that is ... media reported Friday . ,The drug also ... Health Organization (WHO), reported The Himalayan Times daily.Doctors at ... 390 typhoid patients. ,,The team compared the ...
... standard explanation of why AIDS/HIV infection in Australia is back ... the virus is not the death sentence it once ... unprotected sex. ,A recent court case in Melbourne ... men and trying to infect 14 others suggests that something ...
... boat on the Yamuna River that flows past India's capital, it's ... water's surface by rotting sewage -- and that's after at ... ,Now, with New Delhi to host the Commonwealth Games ... being built on the stinking river's banks, India must do in ...
... measures to ensure substandard drugs are stopped from reaching ... a raft of safety scandals, state press reported ... will have to abide by new regulations to improve ... corruption within the industry, the China Daily reported. ...
... Dr. Eric A. Cohen, a researcher at the IRCM (Institut ... on Friday, July 13, in PLoS Pathogens a discovery that ... of drugs to combat HIV. ,Human immunodeficiency virus ... called CD4+T lymphocytes in infected individuals, resulting in a compromised ...
Cached Medicine News:Health News:Autoimmune Response in Multiple Sclerosis 2Health News:Millions Spent, but the Indian Capital's River Still Stinks 2Health News:Millions Spent, but the Indian Capital's River Still Stinks 3
This legless table has adjustable height and round post. Pad sold separately....
This table has adjustable height, an integral leg, and blade post. Includes a standard 2" (5 cm) pad....
This table has adjustable height, round post, and universal clamp. Replacement 1" (5 cm) or 2" (2.5 cm) pad sold separately....
... An excellent choice for orthopedic procedures. ... width to 24" for the ... clamps quickly attach to any O.R. ... easy C-Arm access and stability. ...
Medicine Products: